

4basebio PLC

("4basebio" or the "Company")

Appointment of Joint Corporate Broker

14 November 2024 â€“ 4basebio PLC (AIM: 4BB) (â€œ4basebioâ€ or the â€œCompanyâ€), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces the appointment of RBC Capital Markets as the Company's joint corporate broker, to work alongside Cavendish Capital Markets, with immediate effect.

Enquiries

4basebio PLC

Dr. Heikki Lanckriet
Joint Corporate Broker

+44 (0)1223 967 943

RBC Capital Markets

Rupert Walford / Kathryn Deegan
Joint Corporate Broker

+44 (0)20 7653 4000

Cavendish Capital Markets Limited

Geoff Nash / Nigel Birks
Nominated Adviser

+44 (0)20 7220 0500

Cairn Financial Advisers LLP

Jo Turner / Sandy Jamieson / Ed Downes

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Companyâ€™s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
